SINGLE-DOMAIN ANTIBODY AND DERIVATIVES THEREOF TO LIGAND-1 PROTEIN OF PROGRAMMED CELL DEATH (PDLI) Russian patent published in 2020 - IPC C07K16/28 C12N15/13 C12N15/63 A61K39/395 A61P35/00 

Abstract RU 2715595 C2

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a molecule specifically binding ligand-1 protein programmable death (PDL1) and use thereof, for example, as part of a pharmaceutical composition for treating or preventing cancer. Invention also discloses a nucleic acid molecule encoding said PDL1-binding molecule, an expression vector and a host cell for producing a PDL1-binding molecule.

EFFECT: invention provides binding with PDL1 with high affinity and specificity, which leads to blocking PDL1 binding to PD-1.

20 cl, 24 dwg, 7 tbl, 6 ex

Similar patents RU2715595C2

Title Year Author Number
FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME 2014
  • Govindappa Nagaraj
  • Soares Maria Melina
  • Sastry Kedarnath
RU2662991C2
FUSED IMMUNOMODULATORY PROTEINS AND METHODS FOR PRODUCTION THEREOF 2014
  • Govindappa Nagaraj
  • Soares Maria Melina
  • Sastry Kedarnath
RU2698975C2
PD-1 ANTIBODIES AND USE THEREOF 2016
  • Gu, Nana
  • Shao, Ke
RU2722451C1
NANOANTIBODY SPECIFICALLY BINDING MUC1 PROTEIN, METHOD OF MUC1 PROTEIN DETECTION BY NANOANTIBODIES 2012
  • Tillib Sergej Vladimirovich
RU2493165C1
NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN 2016
  • Zheng, Yong
  • Li, Jing
  • Gololobov, Gennady
  • Zhang, Xinhua
  • Yang, Baotian
  • Tang, Zhewei
  • Li, Dong
  • Xu, Jianqing
  • Wang, Zhuozhi
RU2757316C2
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS 2013
  • Korman Alan Dzh.
  • Srinivasan Mokhan
  • Van Chanyuj
  • Selbi Mark Dzh.
  • Chen Bin
  • Kardarelli Zhozefin M.
RU2599417C2
NANOANTIBODY SPECIFICALLY BINDING CEA PROTEIN, METHOD OF ITS USAGE FOR DETECTION OF THIS PROTEIN 2012
  • Tillib Sergej Vladimirovich
RU2493166C1
HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS 2006
  • Korman Alan Dzh.
  • Srinivasan Mokhan
  • Van Chanjuj
  • Selbi Mark Dzh.
  • Chehn' Bin
  • Kardarelli Zhozefin M.
  • Khuan Khajchun'
RU2494107C2
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS 2006
  • Korman Alan Dzh.
  • Srinivasan Mokhan
  • Van Chanjuj
  • Selbi Mark Dzh.
  • Chehn' Bin
  • Kardarelli Zhozefin M.
RU2406760C2
ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES 2007
  • Ljan Vehj-Ting
  • Sakanaka Tie
  • Vu Jan
RU2448980C2

RU 2 715 595 C2

Authors

Xu, Ting

Dong, Yanrong

Wang, Pilin

Chen, Ting

Dates

2020-03-02Published

2016-08-01Filed